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Ovarian cancer (OC) is the leading cause of death in women with
gynaecological malignancies. In the USA in 1996 approximately
24 000 OC were diagnosed with 13 600 deaths, and in Germany
6400 cases with a similar death rate (Beckmann et al, 1996a).
Because of the absence of early symptoms the majority of patients
are diagnosed with advanced stages. Existing therapeutic
measures are often ineffective and the prognosis of the patients
is poor.
Molecular genetic alterations play a key role in carcinogenesis.
Understanding genetic events that lead to initiation and progres-
sion of ovarian cancer remains an important challenge in gynaeco-
logical research.
Multiple genetic changes, including activation of proto-
oncogenes and inactivation of tumour suppressor genes, are
involved in the genesis and progression of human cancers. Some
associations of genetic alterations with OC development has been
reported. Among them the involvement of chromosome 9 is 
very noticeable. It was first reported by Cliby et al (1993) and
confirmed by others using loss of heterozygosity (LOH) analysis
(Chenevix-Trench et al, 1994; Osborne and Leech, 1994). The
most frequent LOH region on chromosome 9p is next to D9S171
(Chenevix-Trench et al, 1994; Shih et al, 1997). This indicates a
potential tumour suppressor gene in this region involved in the
tumorigenesis of ovarian cancer.
The CDKN2A (also called CDKN2, MTS1, CDK4I) gene was
identified as a candidate tumour suppressor gene within this
chromosomal region (Kamb et al, 1994). It encodes the cyclin-
dependent kinase inhibitor protein p16, a negative cell cycle
regulator. Binding of p16 to CDK4 prevents the association of
CDK4 with cyclin D1. Phosphorylation of substrates essential for
G1 transition of the cell cycle is subsequently inhibited (Serrano
et al, 1993). Inactivation of the CDKN2A gene may therefore
lead to uncontrolled cell growth. In primary ovarian cancer,
mechanisms of the CDKN2A gene inactivation remains unclear.
Intragenic mutations and homozygous deletions were shown to be
rare events (Campbell et al, 1995; Hatta et al, 1995; Shih et al,
1997). Methylation status and expression pattern were reported
mainly with conflicting results (Fujita et al, 1997; Shih et al,
1997). To determine the role of the CDKN2A gene in the develop-
ment of ovarian carcinoma, LOH at 9p21, homozygous deletion,
mutation and methylation status of the CDKN2A gene as well as
its expression at mRNA and protein levels were analysed in a
panel of sporadic ovarian tumours.
MATERIALS AND METHODS
Samples
Samples used in this study (n = 33; 23 OCs, ten benign samples)
were collected from patients (informed consent) during the time of
primary surgery at the Department of Obstetrics and Gynaecology,
Heinrich-Heine University, Düsseldorf, Germany. Only serous
epithelial carcinoma were included. Pathological grades were
G1 = two, G2 = 11 and G3 = ten cases. Clinical stage of OC
patients were stage I+II = nine and III+IV = 14 cases. Three
benign serous cystoma and seven normal ovarian samples were
also analysed. For these samples the superficial cell layers were
used. None of the patients received chemotherapy or endocrine
treatment prior tumour excision. Surgically removed tissues were
snap frozen (liquid nitrogen, –80°C) for later extraction of DNA
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and RNA (Niederacher et al, 1997). Haematoxylin & eosin (H&E)
staining was used for routine pathological evaluation. The content
of tumour cells in the samples analysed was more than 70%. As a
source of normal DNA peripheral blood was used.
LOH analysis of loci 9p21–22
Eight microsatellite markers at 9p21–22 were analysed. Primers
used and polymerase chain reaction (PCR) amplification condi-
tions are shown in Table 1. Primer sequences were obtained from
the Genome Data Base (http://www.gdb.org/) and purchased from
Pharmacia (Freiburg, Germany). One primer of each pair was
(Cy5) fluorescent-labelled at the 5¢ end. PCR products were
analysed in an automated laser-activated fluorescent DNA
sequencer (A.L.F. express, Pharmacia Biotech). The assessment of
allele loss were performed as described previously (Niederacher et
al, 1997).
Homozygous deletion analysis of CDKN2A gene
Homozygous deletion (HD) of CDKN2A gene was determined by
fluorescent differential PCR (fd-PCR) (An et al, 1995).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
as internal standard. PCR products were analysed in a DNA
sequencer and assessment of HD was performed using AlleleLinks
software (Amersham Pharmacia Biotech). Deletion status of the
first and second exon of CDKN2A gene was analysed, respec-
tively. Normal DNA from peripheral blood leucocytes was used as
control. Reduction of the ratio CDKN2A:GAPDH of more than
50% compared with that in the normal controls was considered to
present a HD.
Mutation analysis of CDKN2A gene
Mutation status of the CDKN2A gene was determined by EMD
(enzymatic mutation detection) (Del Tito et al, 1998) using
PassportTM Mutation Scanning Kit (Amersham Pharmacia
Biotech). EMD was performed according to the protocol provided
by the manufacturer. Briefly, 20 ml PCR products were denatured
at 95°C for 5 min followed by hybridization at room temperature
for 30 min. Then, 2 ml T4 Endonuclease VII were added and
cleavage was performed at 37°C for 30 min. Final products were
analysed in a DNA sequencer and assessment was performed
using ALFwinTM Fragment Analyser 1.01 (Amersham Pharmacia
Biotech). The mutation status of the first and second exon of
CDKN2A gene was analysed respectively. Primer used and PCR
conditions are shown in Table 1.
Methylation analysis of CDKN2A gene
The methylation status of CpG islands within the CDKN2A
gene were analysed by PCR-based methylation assay
Table 1 Primers used and PCR conditions
Length of Annealing No. of
Primer Sequence PCR product temperature cycles Use
(bp) (°C)
D9S157 AGCAAGGCAAGCCACATTTCa 133–155 55 28 LOH
TGGGGATGCCCAAGTAACTATATC
D9S162 GCAATGACCAGTTAAGGTTCa 172–196 55 28 LOH
AATTCCCACAACAAATCTCC
IFN-a GTAAGGTGGAAACCCCCACTa 138–150 55 28 LOH
TGCGCGTTAAGTTAATTGGTT
D9S942 GCAAGATTCCAAACAGTAa 100–130 55 27 LOH
CTCATCCTGCGGAAACCATT
D9S171 AGCTAAGTGAACCTCATCTCTGTCTa 159–177 55 27 LOH
ACCCTAGCACTGATGGTATAGTCT
D9S126 ATTGAAACTCTGCTGAATTTTCTGa 225–250 56 34 LOH
CAACTCCTCTTGGGAACTTGC
D9S169 AGAGACAGATCCAGATCCCAa 259–275 55 28 LOH
TAACAACTCACTGATTATTTAAGGC
D9S161 TGCTGCATAACAAATTACCACa 119–135 56 32 LOH
CATGCCTAGACTCCTGATCC
CDKN2A GCGCTACCTGATTCCAATTCa 340 60 35 exon 1 Methyl.
Exon 1 GAAGAAAGAGGAGGGGCTG 26 exon 1 HD
32 exon 1 EMD
CDKN2A ACAAGCTTCCTTTCCGTCATa 235 60 26 exon 2 HD
Exon 2 GCGCACGTCCAGCCGCGCCCCGG
CDKN2A GGAAATTGGAAACTGGAAGC 509 56 35 exon 2 Methyl.
Exon 2 TCTGAGCTTTGGAAGCTCTa
CDKN2A ACAAGCTTCCTTTCCGTCATa 422 64 32 exon 2 EMD
Exon 2 TCTGAGCTTTGGAAGCTCTa
GAPDH 1 TGTGCTCCCACTCCTGATTTCa 200 ref. for fd-PCR
CAAAGGGCAGGAGTAAAGGTC
CDKN2A GCCCAACGCACCGAATAGTa 261 60 37 expression
Expression CGATGGCCCAGCTCCTCAG
GAPDH 2 CCATGGAGAAGGCTGGGGa 195 60 27 ref. for fd-RT-PCR
CAAAGTTGTCATGGATGACC
HD, homozygous deletion; Methyl., methylation; ref., reference. aFluorescent labelled.1922 H-Y Yan et al
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(Gonzalez-Zulueta et al, 1995; Lo et al, 1996). Briefly, 1 mg of
genomic DNA was digested by 10 U SmaI, CfoI or HpaII sepa-
rately (at 30°C, 37°C, 37°C respectively) for 12 h. Thereafter,
10 U enzymes were added and digestion continued for another 12
h. Digested DNA was subjected to PCR. Methylation status of the
first and second exon of CDKN2A gene was analysed separately.
The primers used (Table 1) amplified exon 1, a 340 bp fragment
including one SmaI, four CfoI and two HpaII sites, and exon 2,
a 509 bp fragment including one SmaI, seven CfoI and four HpaII
sites. GAPDH was co-amplified as an internal control. Digested
DNA from normal tissue was used as negative control to ensure
that digestion was complete. Undigested DNA was amplified as
positive control.
CDKN2A gene mRNA expression
Total cellular RNA was isolated using TRIZOL (Gibco-BRL,
Glasgow, UK). One microgram RNA was subjected to digestion
by DNAase I (Gibco-BRL, Rockville, MD, USA) according to the
protocol provided by the producer. A total of 0.86 mg of the
digested RNA was used for cDNA synthesis. Briefly, digested
RNA was denatured at 90°C for 5 min and transcribed by Mulv-
Reverse-Transcriptase (Pharmacia, Freiburg, Germany) using
hexanucleotide (random-) primers. Final reaction volume of 20 ml
contained 50 mM potassium chloride, 10 mM Tris–HCl, 7.5 mM
magnesium chloride, 0.1 mg ml–1 bovine serum albumin (BSA),
15 mM dithiothreitol (DTT), 1 mM each dNTP, 1 U ml–1 RNAasin
(Promega), 1000 pmol random-primers, 9.5 U Mulv-Reverse-
Transcriptase. The conditions were: 26°C for 10 min, 42°C for
45 min and 95°C for 5 min. A 2 ml cDNA aliquot corresponding to
86 ng of RNA was used as template for the reverse transcription
PCR (RT-PCR) amplification. Primers used were shown in Table
1. GAPDH was co-amplified as internal standard. To maintain
both amplifications (CDKN2A and GAPDH) in the exponential
phase a ‘drop-in’ method was used for the differential RT-PCR.
Thirty-seven cycles were performed for CDKN2A and 27 cycles
for GAPDH. PCR products were analysed in a DNA sequencer
and assessment was performed as above. mRNA levels in OC were
compared to that in normal ovarian tissues. Expression level below
the normal range was considered as low, above the normal range as
high expression.
Immunohistochemistry
Immunohistochemical staining for CDKN2A gene product p16
was performed on paraffin-embedded formalin-fixed sections
using the indirect avidin–biotin peroxidase method as described
previously (Beckmann et al, 1996c). Representative paraffin
blocks were sectioned at 5 mm, affixed to 0.02% poly-L-lysine-
coated slides and dried. Sections were dewaxed in xylene and
rehydrated through descending grade alcohol to phosphate-
buffered saline (PBS) (pH 7.4), followed by digestion with 0.1%
trypsin for 20 min, incubation in methanol with 0.03% hydrogen
peroxide for 20 min and 30% normal horse serum 20 min at room
temperature. Sections were then incubated with mouse anti-
human p16 monoclonal antibody (1:300 dilution, Pharmingen, San
Diego, CA, USA) overnight at 4°C. This was subsequently
followed by biotinylated horse anti-mouse antibody (1:100) and
by avidin–biotin–peroxidase complex (Vector Laboratories,
Burlingame, CA, USA). As negative control, irrelevant mouse
monoclonal IgG was applied as the primary antibody. A known
p16-positive epithelial tissue sample was used as positive control.
Immunoreactivity of p16 was quantified by counting staining
positive and negative tumour cells in a minimal total of 1000 cells.
The relative number of immunoreactive cells was graded as
follows: < 10% = –, 10–50% = +, >50% = ++. Intensity of staining
was not evaluated.
Statistical analysis
Statistical analysis was performed by using SPSS (8.0) software.
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Figure 1 LOH analysis of marker D9S162 (x-axis: run time (min)). Lane 4: normal blood DNA, lane 24: tumour DNA with signal reduction (80%) in the second
alleleCDKN2A gene inactivation in sporadic ovarian cancer 1923
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RESULTS
LOH on chromosome 9p21–22
Paired normal and tumour DNA from 23 malignant tumours and
three benign tumours were analysed for LOH. No LOH was found
in the benign tumours. Of the 23 malignancies analysed, 15 (65%)
showed LOH of at least one or more microsatellite markers.
Representative examples of LOH are shown in Figure 1.
Frequencies of LOH in the tumour panel varied according to the
markers tested. D9S157 and D9S169 showed the least frequent
(40%) and D9S942, IFN-a and D9S171 the most frequent LOH
rates (59%, 53% and 53% of informative cases respectively). In
seven of the 15 tumours with allele loss, all informative markers
showed LOH, suggesting that in these tumours a large region of
9p21–22 was lost. Eight tumours with partial deletion pattern are
illustrated in Figure 2. Most of the tumours (7/8) showed a
common region of deletion between marker IFN-a and D9S171
including the CDKN2A gene. Only one tumour (T2) with
heterozygous marker D9S942 may further restrict the SRO
(smallest region of overlap) between markers D9S942 and
D9S171, but marker IFN-a is not informative in this tumour (T2).
The minimum LOH rate for the CDKN2A gene locus estimated by
the extragenic markers (IFN-a and D9S942) was 39%.
Homozygous deletion and mutation of CDKN2A gene
Homozygous deletion and mutation status of the CDKN2A gene
were analysed in all the tumours. No homozygous deletion was
found. There was no evidence of mutation in both exons of the
CDKN2A gene.
Methylation of the CDKN2A locus
Methylation status of exon 1 and 2 of the CDKN2A gene was
analysed separately. Of the 33 ovarian samples analysed (23
malignant epithelial tumours, three benign tumours and seven
normal ovarian tissue samples), six malignant tumours showed
methylation in exon 2, but none showed methylation in exon 1.
Exon 2 methylation did not correlate to pathological grade and
clinical stage of the patients and had no association with reduction
of mRNA and protein expression of the CDKN2A gene. No
methylation was found in both exons in either the benign tumours
or the normal ovarian tissues.
Expression of CDKN2A gene at mRNA and protein level
The mRNA level of CDKN2A gene was examined in a total of 22
frozen ovarian cancers and seven normal ovarian tissues by differ-
ential RT-PCR (Figure 3). Of 22 tumours analysed, low expression
of the CDKN2A gene was detected in six tumours and high expres-
sion in eight tumours. The expression of the CDKN2A gene was
not significantly associated with histological grade and clinical
stage.
The CDKN2A gene product p16 was investigated by immuno-
histochemistry in 19 ovarian cancers and seven normal ovarian
tissues. In normal ovarian tissue the epithelium showed weak posi-
tive staining. Of the 19 OCs examined, 15 showed positive
staining (+/++) and four tumours were negative. The immuno-
staining correlated with CDKN2A mRNA level (P = 0.038, Table
2), but was not significantly associated with pathological grade
and clinical stage of patients (data not shown).
CDKN2A gene expression (mRNA and protein) and LOH at
CDKN2A gene locus (D9S942 and IFN-a) were not significantly
associated (Table 3).
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Figure 2 Schematic representation of eight patients with partial deletions at 9p21–22. (n), LOH; (n n), not informative; (n n), retention of heterozygosity; (n),
largest possible region of deletion1924 H-Y Yan et al
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DISCUSSION
LOH studies have been widely used to identify chromosome
regions which may contain putative tumour suppressor genes.
Frequent LOH on chromosome 9p has been observed in multiple
tumour types including sporadic ovarian cancer. This indicates the
presence of tumour suppressor gene(s) in this region involved in
the tumorigenesis in a wide variety of tumours (Eiriksdottir et al,
1995; Kishimoto et al, 1995; Schultz et al, 1995; Devlin et al,
1996). In this study, LOH analysis at eight loci of 9p21–22 was
performed in 23 serous papillary OCs by using a sensitive analyt-
ical method based on fluorescent PCR technology (Beckmann et
al, 1996b; Niederacher et al, 1997). LOH at 9p was demonstrated
in 15 of 23 (65%) tumour samples. A most common deleted region
could be defined between IFN-a and D9S171; this is in good
agreement with previous observations (Chenevix-Trench et al,
1994). The high frequency of LOH at 9p21 gives a strong hint to a
tumour suppressor gene(s) located in this region, which is
involved in the tumorigenesis of sporadic ovarian carcinomas.
The CDKN2A gene is the most common candidate gene in this
region. It has been found to be inactivated by intragenic mutations
and homozygous deletions in a variety of tumour-derived cell lines
such as lung cancer, oesophagus cancer, malignant melanomas and
gliomas (Chenevix-Trench et al, 1994; Kamb et al, 1994; Nobori 
et al, 1994). However, for most primary tumours including OC,
mutations and homozygous deletions have been found to be much
less frequent than in cancer cell lines (Cairns et al, 1994; Spruck
et al, 1994; Campbell et al, 1995; Shih et al, 1997). More interest-
ingly, in sporadic OC, CDKN2A mutations strongly associate with
specific tumour subtypes. High frequency of mutation was found
in mucinous and endometrioid OC, but very low in serous papil-
lary OC (Milde-Langosch et al, 1998). Our study is in good agree-
ment with this finding. Of 23 serous papillary OCs no mutation
was found by using EMD, a novel mutation detection technique,
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Figure 3 CDKN2A expression analysis by fd-RT (x-axis: base pair) in ovarian cancer. First peak: reference gene GAPDH (195 bp), second peak: CDKN2A
gene (261 bp). Lane 13: normal ovarian tissue, lane 5: ovarian cancer (T15) showed low expression (signal reduced 58% compared to normal ovarian tissues),
lane 3: ovarian cancer (T10) showed high expression (signal increased three-fold compared to normal ovarian tissues)
Table 2 Relationship between CDKN2A mRNA and protein expression
(n = 18)
Protein
–+ + +
mRNA
Low 2 1 1
Medium 1 4 3
High 0 0 6
P = 0.038
By c2 test.
Table 3 Relationship between CDKN2A gene expression and LOH at
CDKN2A locus
mRNA protein
Low Medium High – + ++
LOH 1 4 2 2 3 3
No LOH 5 4 6 2 2 7
P > 0.05 P > 0.05
By c2 test.CDKN2A gene inactivation in sporadic ovarian cancer 1925
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which has been used as routine scanning method for BRCA1/2
mutation in our laboratory. Homozygous deletion has been shown
to be very rare in primary tumours including OC, regardless of the
tumour subtype (Fujita et al, 1997; Milde-Langosch et al, 1998). In
this study no homozygous deletion was found in 23 serous papil-
lary OCs analysed. This further confirms that homozygous
deletion does not seem to be a mechanism of CDKN2A gene
inactivation in sporadic OC.
Beside mutation and homozygous deletion, an alternative
pathway involving hypermethylation of the 5¢ CpG island has been
found to inactivate the CDKN2A gene by blocking CDKN2A tran-
scription in a variety of tumours (Merlo et al, 1994; Costello et al,
1996; Lo et al, 1996). Methylation status of the CDKN2A gene in
OC has been rarely reported and with conflicting results: no
methylation (0/50) (Shih et al, 1997) and 14% (8/43) (Fujita et al,
1997). A recent study (Milde-Langosch et al, 1998) showed that
methylation also seemed to be specific for tumour histological
subtype. It presents much higher frequency in mucinous and
endometrioid subtype than in serous papillary OC. To gain further
insight to the possible role of CDKN2A gene methylation in
ovarian carcinogenesis CpG island methylation status in exon 1
and 2 of the CDKN2A gene was investigated. In 23 serous papil-
lary OCs analysed there was no evidence of methylation in exon 1.
However, methylation of the second exon was found in seven
cases. Methylation of exon 1 is considered to completely block the
CDKN2A gene transcription (Merlo et al, 1995), but the mecha-
nism of action of exon 2 methylation remains unclear (Gonzalez-
Zulueta et al, 1995). In this study exon 2 methylation existed only
in ovarian malignancy, but not in normal ovarian tissue and benign
tumours. This implies that exon 2 methylation is to some extent
involved specifically in the malignant transformation. Correlation
of exon 2 methylation with gene expression level was not found
suggesting that other mechanisms than transcriptional suppression
may be involved.
Although conventional inactivation mechanisms of the
CDKN2A gene, such as mutation, homozygous deletion and
5¢-CpG island methylation rarely occurred in serous papillary OC,
we found that absence of CDKN2A gene expression was not a rare
event in these tumours with 27% (6/22) at mRNA level and 21%
(4/19) at protein level. Among six tumours without CDKN2A
mRNA expression, none of the known inactivation mechanisms
could be detected, suggesting that other mechanisms than those
examined might be involved. Interestingly, this study showed a
tendency that high CDKN2A expression correlated to higher
pathological grade and advanced clinical stage, which is in agree-
ment with Fujita et al (1997) and Dong et al (1997). Fujita et al
investigated CDKN2A expression in 60 OCs and concluded that
loss of p16 correlated to longer survival. Dong et al showed in a
much larger immunohistochemical study including 190 epithelial
ovarian tumours that loss of p16 is associated with lower patho-
logical grade, earlier clinical stage and better prognosis. Similar
results were also shown by Shigemasa et al (1997) and Milde-
Longosch et al (1998). These findings seem to be controversial to
the negative regulatory function of p16 in cell cycle control and
suggest unknown inactivating mechanisms of the CDKN2A gene
in OC. Obviously, genomic alterations at DNA level such as dele-
tion, mutation and methylation influence CDKN2A gene expres-
sion significantly. On the other hand, p16 is in a complicated
feedback loop constituted by CDK4, cyclin D1, pRb and some
transcriptional factors, which can regulate CDKN2A gene expres-
sion at transcription level (Serrano et al 1993; Kamb et al, 1994).
Besides this, other bypassing pathways such as cyclin E1 is also
supposed to regulate p16 expression indirectly (Gray-Babin et al,
1996). Therefore, it could be interpreted that reduced CDKN2A
gene expression may play a key role in the early development of
OC. With the progression during OC expression of the CDKN2A
gene might be regulated by: (1) other cancer-related gene(s)
involved and (2) some transcriptional factors changing with cell
proliferation. Therefore, the level of CDKN2A gene expression is
actually an indicator for the cell status. This interpretation is
further supported by the result that LOH at CDKN2A locus does
not correlate with CDKN2A mRNA level. CDKN2A gene mRNA
level correlated significantly with the protein level, further
indicating that post-transcriptional regulation of protein level does
not seem to play a role in the CDKN2A expression.
Our result showed that the SRO flanked widely from D9S171 to
D9S942 and IFN-a. Besides the CDKN2A gene there could be
other tumour suppressor gene(s) involved in the tumorigenesis of
OC, such as the p15 gene or p19 gene, a novel tumour suppressor
gene sharing exon 2 with the CDKN2A gene.
In conclusion, the results in this study suggest that there is a
tumour suppressor gene(s) at 9p21 involved in the tumorigenesis
of OC. The CDKN2A gene may be the candidate gene in this
region. The inactivation of this gene showed to be tumour subtype
specific. In mucinous and endometrioid OC mutation and methyl-
ation present the major inactivation mechanisms. But in serous
papillary OC the inactivation mechanism remains unclear.
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